Panacea Index Logo

Command Palette

Search for a command to run...

Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting.

Neurology
January 1, 1970
Ergun Y Uc et al. (16 authors)
Clinical Trial, Phase IClinical Trial, Phase IIJournal ArticleRandomized Controlled TrialResearch Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, Non-P.H.S.Human StudyClinical
Study Details

Study Goal

The researchers aimed to investigate the effects of aerobic walking on motor function, cognition, and quality of life in Parkinson's disease (PD) and compare the safety, tolerability, and fitness benefits of different exercise regimens.

Results Summary

The study found that aerobic walking improved aerobic fitness, motor function, fatigue, mood, executive control, and quality of life in mild to moderate PD, with no serious adverse events reported. Preliminary analyses suggested higher musculoskeletal adverse events in the interval training group, leading to a shift to continuous training.

Population

Independently ambulatory patients with mild to moderate Parkinson's disease.

Effective Dosage

3 times per week, 45 minutes per session.

Duration

6 months.

Interactions

None mentioned.

Extracted Claims (27)
InterventionDirectionEndpointPopulationDosageImpactClaim #
aerobic walking
increase
motor function
mild to moderate PD
-
improves
#1
aerobic walking
increase
cognition
mild to moderate PD
-
improves
#2
aerobic walking
increase
quality of life
mild to moderate PD
-
improves
#3
aerobic walking
increase
aerobic fitness
mild to moderate PD
-
improves
#4
aerobic walking
decrease
fatigue
mild to moderate PD
-
improves
#5
aerobic walking
increase
mood
mild to moderate PD
-
improves
#6
aerobic walking
increase
executive control
mild to moderate PD
-
improves
#7
aerobic walking
no change
safety
mild to moderate PD
-
is safe
#8
aerobic walking
no change
tolerability
mild to moderate PD
-
is well tolerated
#9
aerobic exercise program
increase
aerobic fitness
patients with PD
-
improves
#10
aerobic exercise program
increase
motor function
patients with PD
-
improves
#11
aerobic exercise program
decrease
fatigue
patients with PD
-
improves
#12
aerobic exercise program
increase
mood
patients with PD
-
improves
#13
aerobic exercise program
increase
cognition
patients with PD
-
improves
#14
interval training
increase
musculoskeletal adverse events
participants
-
suggested higher musculoskeletal adverse events
#15
interval training
no change
improving fitness
-
-
lack of difference
#16
continuous training
no change
improving fitness
-
-
lack of difference
#17
aerobic walking
increase
maximum oxygen consumption
all completers
-
observed improvements
#18
aerobic walking
increase
gait speed
all completers
-
observed improvements
#19
aerobic walking
decrease
Unified Parkinson's Disease Rating Scale sections I and III scores
all completers
-
observed improvements
#20
aerobic walking
decrease
fatigue
all completers
-
observed improvements
#21
aerobic walking
decrease
depression
all completers
-
observed improvements
#22
aerobic walking
increase
quality of life
all completers
-
observed improvements
#23
aerobic walking
increase
flanker task scores
all completers
-
observed improvements
#24
aerobic walking
increase
increase in maximum oxygen consumption
-
-
correlated
#25
aerobic walking
increase
improvements on the flanker task
-
-
correlated
#26
aerobic walking
increase
improvements on quality of life
-
-
correlated
#27
Abstract

OBJECTIVES: To (1) investigate effects of aerobic walking on motor function, cognition, and quality of life in Parkinson disease (PD), and (2) compare safety, tolerability, and fitness benefits of different forms of exercise intervention: continuous/moderate intensity vs interval/alternating between low and vigorous intensity, and individual/neighborhood vs group/facility setting. METHODS: Initial design was a 6-month, 2 × 2 randomized trial of different exercise regimens in independently ambulatory patients with PD. All arms were required to exercise 3 times per week, 45 minutes per session. RESULTS: Randomization to group/facility setting was not feasible because of logistical factors. Over the first 2 years, we randomized 43 participants to continuous or interval training. Because preliminary analyses suggested higher musculoskeletal adverse events in the interval group and lack of difference between training methods in improving fitness, the next 17 participants were allocated only to continuous training. Eighty-one percent of 60 participants completed the study with a mean attendance of 83.3% (95% confidence interval: 77.5%-89.0%), exercising at 46.8% (44.0%-49.7%) of their heart rate reserve. There were no serious adverse events. Across all completers, we observed improvements in maximum oxygen consumption, gait speed, Unified Parkinson's Disease Rating Scale sections I and III scores (particularly axial functions and rigidity), fatigue, depression, quality of life (e.g., psychological outlook), and flanker task scores (p < 0.05 to p < 0.001). Increase in maximum oxygen consumption correlated with improvements on the flanker task and quality of life (p < 0.05). CONCLUSIONS: Our preliminary study suggests that aerobic walking in a community setting is safe, well tolerated, and improves aerobic fitness, motor function, fatigue, mood, executive control, and quality of life in mild to moderate PD. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in patients with PD, an aerobic exercise program improves aerobic fitness, motor function, fatigue, mood, and cognition.

Medical Subject Headings (MeSH)
AgedAged, 80 and overExerciseFemaleHumansMaleMiddle AgedParkinson DiseaseQuality of LifeResidence CharacteristicsTreatment Outcome
Study Links
Quality Scores
Safety90
Efficacy85/10
Quality75/10
Citation Metrics
Total Citations159
Citations/Year14.5
Relative Citation Ratio6.74
NIH Percentile95.7%
Research Impact Scores
APT Score0.95
Weight Score1.93
Normalized Score0.85
Related Supplements
Phase I/II randomized trial of aerobic exercise in Parkinson... | Panacea Index